Obesity drug Cagrisma will be an important product

Copenhagen, Denmark – Novo Nordisk Multi-hipkli, the next generation of obesity candidate candidate candidate candidate defended the results of disappointed tests for Cagrisma, there will be a “important” weight loss treatment.

CEO Lars Frugaard Jørgensen acknowledged the reaction of a sharp stock price after the company’s weight decreases after two consecutive late-stage tests, but thus “promoted” the medicinal weight loss profile.

“I’m very confident in the CAGRISEMA,” he said.

“It will be an important product for us.”

CAGRISEMA is a combination of Cagrisis – an amillin analogue and semaglutide is a form of washing form of weight loss, known as an active ingredient in Wegovy.

Title results re-determined-2 late-stage testing released At the beginning of this month, CagRisema showed 8.7% of Obese or overweight adult patients with more than 68 weeks compared to 2.1%, placebo in 68 weeks. This was before the forecast, according to the percentage of high-ranking young people.

A late stage test before published In December, he showed the medicine or had one or more commandericity, but in 68 weeks of Tip-2, 22.7% in 68 weeks, weight 22.7%, 25%.

Both results chose a significant value from Novo’s stock price Eli lily Zepbound, both GLP-1 medication, traffic jammed. Once Darling Stock is now more than 50% of the heights of 2024.

The Danish pharmaceutical giant once faced a spray on Thursday, because shareholders were tacted to provide a clearer and tactical voice tests and targets less dramatic stock prices.

Frugaard Jørgensen, especially after 68 weeks, a flexible test design, which is less than two-thirds of patients who progress in the highest dose, admitted that the company does not clearly deliver a flexible test design.

“22.7% are 25%, so some people have been disappointed,” the company said, “the company believes that the cagmentation has a continuous potential to develop the general dose,” he said.

Novo Nordisk has now conducted a new test 3 tests, “will investigate the potential of the CagRisema to 2.”

The weight loss industry comes as part of obesity medications outside the total weight reduction and the results are divided into the results. In the beginning of this month, Bofa said that the global study of Bofa, obesity and diabetes “slightly more cautious in distinction”.

However, in Sydbank, Pharma capital analyst Soren Lontoft, tell Last week, CNBC was needed by various treatments to solve both obesity and endurance levels, but also cardiovascular disease, sleep apnea and liver disease.

“It is clear that there is a great market opportunity, but it also receives a portfolio of products that meet the needs of different patients,” said Frugaard Jørgensen.